Evidence map›Paper›PMID 25843605›Full record

ArticleMethods (San Diego, Calif.)2015

Fabrication and characterization of injectable hydrogels derived from decellularized skeletal and cardiac muscle.

J L Ungerleider, T D Johnson, N Rao, K L Christman

Abstract read
In one paragraph

Article in Methods (San Diego, Calif.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 147 citations in OpenAlex.

  1. Article
  2. Decellularized cardiac ECM: A tissue-specific bioactive platform for drug release and cell delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Novel muscle-derived extracellular matrix hydrogel promotes angiogenesis and neurogenesis in volumetric muscle loss.Matrix biology : journal of the International Society for Matrix Biology · 2024
    Article
  16. Review
  17. A review of advanced hydrogels for cartilage tissue engineering.Frontiers in bioengineering and biotechnology · 2024
    Review
  18. Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

J L UngerleiderDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
T D JohnsonDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
N RaoDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
K L ChristmanDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA. Electronic address: christman@eng.ucsd.edu.
University of California, San Diego · US

Funding

Extracellular matrix hydrogels for treating ischemiaR01HL113468 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHRISTMAN, KAREN L · 2012 to 2020
$3.1M
NHLBI NIH HHS R01 HL113468NHLBI NIH HHS R01HL113468
6 · The paper itself

Abstract

Biomaterials, which can contain appropriate biomechanical and/or biochemical cues, are increasingly being investigated as potential scaffolds for tissue regeneration and/or repair for treating myocardial infarction, heart failure, and peripheral artery disease. Specifically, injectable hydrogels are touted for their minimally invasive delivery, ability to self-assemble in situ, and capacity to encourage host tissue regeneration. Here we present detailed methods for fabricating and characterizing decellularized injectable cardiac and skeletal muscle extracellular matrix (ECM) hydrogels. The ECM derived hydrogels have low cellular and DNA content, retain sulfated glycosaminoglycans and other extracellular matrix proteins such as collagen, gel at physiologic temperature and pH, and assume a nanofibrous architecture. These injectable hydrogels are amenable to minimally invasive, tissue specific biomaterial therapies for treating myocardial infarction and peripheral artery disease.

Indexed as

AnimalsBiocompatible MaterialsBiomechanical PhenomenaCell SeparationExtracellular MatrixGlycosaminoglycansHydrogelsInjectionsMaterials TestingMuscle, SkeletalMyocardial InfarctionMyocardiumPeripheral Arterial DiseaseSus scrofaTissue EngineeringBiocompatible MaterialsGlycosaminoglycansHydrogelsDecellularizationExtracellular matrixHydrogelMyocardial infarctionPeripheral artery disease

Identifiers

PMID25843605
PMCPMC4526417
OpenAlexW1994077842

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.